Summary Type and extent of endocrinological alterations were studied in long-term disease-free survivors after cisplatin-based chemotherapy for testicular cancer. A total of 63 patients with a median age of 30 (19 -53) years, and median follow-up of 42 (16-128) months were included. Elevated serum follicle-stimulating hormone (FSH) levels were found in 63% of patients, 24% showed pathologically elevated luteinising hormone (LH) levels with normal and 10% with subnormal testosterone levels. The degree of gonadotropin elevation was highly significantly correlated with the cumulative platinum (P) dose. Patients treated with platinumvinblastine -bleomycin regimens showed higher gonadotropin levels than those treated with platinumetoposide-bleomycin. The adrenal androgen dehydroepiandrosterone (DHEA), pathologically elevated in 68% of patients, was significantly correlated with the cumulative doses of chemotherapy (ctx) used and to the gonadotropin levels. Treatment variables, such as type and dose of cytotoxic agents used, as well as degree of gonadotropin elevation were further correlated with changes in oestron, testosterone and 17a-OH-progesterone levels. Cholesterol levels were elevated in 32% of patients and significant interactions between the steroid hormone levels and cardiovascular risk factors could be shown.
Alterations in the hormonal equilibrium seem to persist in more than 50% of young men treated for testicular cancer, disrupting the physiological age-and gender-specific homeostasis of steroid hormones, with potential influence on the development of cardiovascular risk factors.
The introduction of effective chemotherapy (ctx) for patients with metastatic testicular cancer has resulted in a tremendous number of young patients being cured of their malignant disease. Today approximately 80% of patients can be rendered long-term disease free by 3-4 cycles of a combination therapy with cisplatin (P), etoposide (E) and bleomycin (B), followed by secondary surgery. With the success of cytotoxic treatment, possible long-term side-effects have come to be of concern for these young patients who can expect to live for another 30-50 years after treatment of their tumour. In recent years several studies have been conducted concerning later toxicities after ctx for testicular cancer such as neurotoxicity, ototoxicity, vascular toxicity, renal damage and infertility (Aass et al., 1990; Bissett et al., 1990; Roth et al., 1988; Schwabe et al., 1992) , but few data have been available on endocrinological changes, although there is evidence of multiple ctx-related endocrine abnormalities (Bokemeyer et al., 1994; Giona et al., 1994) . The implications of ctx-induced gonadal toxicity go beyond the occurrence of infertility, since subtle shifts in hormonal ratios might influence the physiological equilibrium necessary for maintaining health and well being. Alterations of gonadal hormones and their regulatory proteins may influence multiple body functions, such as bone and mineral homeostasis (Holmes et al., 1994) , steroid metabolism and lipid profiles (Barrett-Connor and Khaw, 1988) .
Information available on serum cholesterol levels after ctx is limited and partially controversial (Ellis et al., 1992; Gietema et al., 1992; Raghavan et al., 1992) and little is known on the potential associations between cholesterol levels and changes of sex hormones or adrenal androgenshormones that themselves have been postulated to be related to life expectancy and ageing (Barrett-Connor et al., 1986) . The interactions between these hormones and cholesterol metabolism may influence the risk of cardiovascular disease. Cases of myocardial infarctions have been observed in the young cohort of patients treated for testicular cancer (Berger et al., 1995; Roth et al., 1988) .
It is the aim of the current study to investigate the type, extent and reversibility of endocrinological alterations in long-term survivors of testicular cancer treated with cisplatinbased combination ctx. In addition, the influence of individual patient characteristics on the occurrence of late endocrinological toxicity is investigated.
Material and methods Patients
A total of 66 of 182 patients treated for testicular cancer at Hannover University Medical School between 1976 and 1987 agreed to take part in a study concerning the detection of possible endocrinological late toxicities following ctx. All patients had been in complete remission for at least 12 months after ctx. Three patients were omitted from this study, two with bilateral orchidectomy and exogenous gonadal hormone substitution and one intersexual patient with primary gonadal dysfunction. The characteristics of the remaining 63 patients included in this study are given in Table I .9 AIU ml-1) and normal T levels, implying compensated Leydig cell insufficiency and impaired spermatogenesis; (4) six (10%) patients with LH and FSH elevation and low T (range: LH 18.1-30.2 yIU ml-', FSH 30.9-49.3 jlU ml-', T 1.5-3.0 ng ml-'), indicating impaired spermatogenesis and decompensated Leydig cell insufficiency; and (5) four (6%) patients with low T only (range: T 2.4-2.9 ng ml-1). For two (3%) patients hormone profiles could not be interpreted. Figure 1 for details). The cumulative cisplatin dose proved to be a significant risk factor for FSH (P = 0.006) and LH (P = 0.01) elevations in all patients and among protocol-stratified subgroups. Comparable cisplatin-and bleomycin-based regimens containing etoposide (PEB) instead of vinblastine (PVB) seemed to result in less gonadal toxicity [LH elevations in 8% vs 33% of patients respectively (NS) and FSH elevation in 50% vs 75% of patients respectively. (P < 0.05)]. Patients who had received both etoposide and vinca alkaloids were at a significantly higher risk for FSH elevations than patients receiving only one of these agents.
Owing to adjustments for a possible bias caused by factors such as differing times of follow-up after different ctx regimens (PEB and PVB) affecting patient age, or the use of higher cumulative cisplatin doses in advanced disease patients, it was necessary to also compare smaller subsets of patients. Patients >28 years at the time of ctx showed a tendency towards higher FSH (Figure 2 ), LH and lower T levels in most subgroups. A statistically significant decrease of gonadotropin levels with time since ctx application was found only for FSH in patients who had received regimens with high gonadal toxicity (cumulative cisplatin dose >400 mg m-2) (P = 0.02). Although as a trend the gonadotropins in this patient group decreased with time, levels still remained elevated compared with normal values despite a median of 57 months of follow-up.
The mean T levels were significantly (P=0.017) influenced by the cumulative cisplatin doses applied (lower T levels in patients with >400 mg m-2 cisplatin compared with patients with .400 mg m-2 cisplatin). Application of steroids for antiemesis during ctx, smoking status, liver function and serum albumin concentration did not significantly influence gonadotropin or T levels.
Adrenal androgens Serum DHEA levels were studied in 28 patients. A total of 19 (68%) patients presented values elevated above the laboratory normal value. Although a physiological age-dependent decline has been described (Zumoff et al., 1980 ) only a minor trend for lower DHEA levels in older patients was noticed although the negative correlation between DHEA and age increased when being controlled for toxicity parameters, such as the cisplatin dose or gonadotropin levels. DHEA levels were significantly correlated to the cumulative dose of cisplatin (CC 0.51; P=0.006). Accordingly, DHEA levels were correlated with LH and FSH levels (CC 0.64; P < 0.001 and 0.55; P=0.003). Similar associations were seen between DHEA and the cumulative doses of etoposide (CC 0.51) and vinblastine (CC 0.66).
A total of 34 patients were studied for serum DHEAS levels. The physiological decrease in DHEAS with age was seen in our patient group with a significant CC of -0.34. Other testicular and adrenal steroids Compared with normal laboratory range values for men, serum 17-OH-pr was elevated in 32 (51%) and tE in 21 (33%) of the 63 patients studied (see Table II ). El and E2 levels were elevated in only eight (13%) and five (8%) of patients. As there was a strong negative correlation between liver function parameters and these steroids, e.g. liver enzyme elevations and El in <30 year-old patients: CC -65; P= 0.002, three patients with alcohol-related major liver dysfunctions were excluded from further evaluation. Unless stated otherwise, the statistical analyses included the remaining 60 patients and the 47 patients with completely normal liver function parameters separately. Minimal elevations of liver parameters were not found to be related to any of the cytotoxic agents or their doses applied during previous ctx and serum albumin concentrations were not found to influence the following calculations.
Positive correlations were established between El levels and DHEA (CC 0.47; P=0.012), and to a lesser degree between El and LH levels (CC 0.27; P=0.035). E2 and T levels were significantly correlated (CC 0.35) as would be expected owing to the shared metabolical pathway. tE levels were only correlated with El at a level of statistical significance (CC 0.30; P = 0.019). The statistically highly significant correlation of 17-OH-pr with T (CC 0.46; P<0.001) was confirmed in all subgroups and accordingly, 17-OH-pr and LH correlated well (CC 0.4; P = 0.002). Furthermore, correlation of 17-OH-pr with DHEA reached statistical significance (CC 0.37; P=0.05).
Patient age was positively correlated with E2 (P=0.018) and negatively to El levels (P= 0.008). The strongest correlation between E2 and tE or T, as well as between 17-OH-pr and T was found in patients < 28 years of age.
El levels seemed to be influenced by the application of vincristine during ctx, with mean El levels of 50.1 pg ml-'in 51 patients without and of 71 pg ml-' in nine patients with vincristine (CC 0.67; P=0.001). A trend towards increased levels of tE and E2 with higher cumulative doses of etoposide applied was observed (NS).
Serum cholesterol and body mass index Total serum cholesterol (Chol) concentrations were measured in all 63 patients and elevation > 6.7 mmol I' occurred in 20 (32%) patients. The body mass index (BMI) -calculated as weight (kg) divided by height squared (m2) -was used as an index for obesity. Based on a cut-off value >25 for BMI, (according to the Broca index), 20 (32%) patients were considered as being overweight.
A highly significant correlation was established for patient age with Chol (CC 0.39) and BMI (CC 0.42). Furthermore, Chol and BMI correlated with each other (CC 0.5; P=0.001; age-adjusted CC 0.34; P=0.03). Since both Chol and BMI were significantly correlated with elevated liver function parameters (CC 0.5; P=0.001) the following analyses were carried out for patients with normal liver functions separately. (Bokemeyer et al., 1984) . In the last decade long-term toxicity has also become relevant to patients with testicular cancer, as the use of combination ctx and the introduction of cisplatin (Einhorn and Donohue, 1977) have resulted in potentially curative treatment. Yet, data on endocrine toxicity in patients with testicular tumours have mainly focused on fertility issues, and only a few investigations were concerned with additional longterm endocrinological abnormalities of hormone metabolism. Besides sporadically documented minor thyroid-stimulating hormone elevations (Bosl and Bajorunas, 1987; Gietema et al., 1992; Leitner et al., 1986; Schwabe et al., 1992) , alterations in oestradiol levels have been found in patients treated for testicular cancer (Gietema et al., 1992; Schwabe et al., 1992) , but the impact of these findings, e.g. on lipid profiles and further metabolic changes, were not investigated.
Although patients with testicular cancer may have an increased incidence of pre-existing gonadal disorders (Carroll et al., 1987) , it is generally accepted that ctx can significantly alter the gonadal function (Bosl and Bajorunas, 1987) . Other factors influencing the regulation of the pituitary-testicular hormone axis may be the malignancy itself, which can adversely affect gonadal function (Blackman et al., 1988) and the secretion of,B-hCG by the tumour, which may influence gonadotropin levels (Cochran et al., 1975) . However, these tumour-associated factors can be disregarded in long-term surviving patients after ctx. An influence of unilateral orchidectomy on sex hormone steroid levels has been denied (Hoeppner et al., 1986) . Therefore, the present study investigates persisting abnormalities in the male steroid hormone equilibrium following different combination ctx protocols for testicular cancer, in order to identify possible endocrinological damage resulting from ctx. Besides the impact of ctx itself, additional variables such as age, time of follow-up, liver metabolism, serum albumin concentration were taken into consideration and all calculations were performed for the total patient population and for appropriately stratified subgroups.
To evaluate testicular function, serum testosterone (T), and the gonadotropins secreted by the pituitary gland, FSH and LH have to be determined (Horton, 1990) . Elevated serum FSH concentrations, probably resulting from deficient secretion of inhibin and sex steroids (Horton, 1990) Despite the pulsatile excretion mode of LH from the pituitary gland, single LH values taken at a set time of day were highly correlated with FSH levels (CC 0.76; P<0.001), indicating the usefulness of single determinations of gonadotropins at a fixed time (Bain et al., 1988) and their value as reliable parameters of gonadal damage.
Controversial data have been reported on the issue of return of fertility with time after ctx (Bissett et al., 1990; Drasga et al., 1983; Hansen et al., 1990; Kreuser et al., 1989) . Our results of 63% elevated FSH levels at a median time of 42 months after ctx (1-11 years) and the degree of FSH elevation, which correlates highly significantly with the cumulative dose of cisplatin administered, imply that the damage to spermatogenesis persists in the majority of patients. Only two of ten patients with elevated FSH levels who were also studied before ctx had previously shown elevated FSH values. The occurrence of gonadal toxicity correlated significantly with cisplatin-induced neuro-and ototoxicity in our patients, confirming the impact of cisplatin-based ctx on gonadal impairment (Berger et al., 1995; Bokemeyer et al., 1993) .
Furthermore, a correlation between cisplatin dose and LH levels was documented. Although normalisation of elevated LH levels with the time of follow-up has been suggested (Leitner et al., 1986) , a relevant decrease in LH and FSH level elevation was seen only in the subset of our patients who had received rather toxic high-dose platinum-based regimens resulting in initially very high gonadotropin levels. In all other treatment groups long-term median LH and FSH elevations persisted or even slightly increased as compared with levels of patients with short observation periods. Thus, our findings do not help enlighten this controversial issue.
A total of 24% of our patients showed endocrinological profiles of a compensated, and 10% of patients of a decompensated, Leydig cell insufficiency. Regarding the median age of 31 years of these patients and the average follow-up of 37 months, impaired Leydig cell function in onethird of all treated patients represents a considerable longterm toxicity. Although the testosterone levels did not decrease any further with the time of follow-up, it is too early to conclude that the compensated Leydig cell insufficiency will return to normal or at least remain stable with time in all patients. Since the median testosterone levels were lower after more toxic regimens -in addition to the physiological decrease in testosterone with age -the increased risk of ctx-treated patients for developing premature Leydig cell insufficiency should be kept in mind.
Most data concerning ctx-related gonadal toxicity for testicular cancer are based on PVB ctx (Einhorn and Donohue, 1977) . Although a similar degree of gonadal toxicity has been postulated for vinblastine (V) and etoposide (E) used as single agents (Hansen et al., 1990) , the current standard regimen for PEB (replacing V by E) was shown to be significantly less gonadotoxic in our patients compared with PVB therapy, when similar cumulative doses of P and B were given. The highest levels of gonadotropins were reached in patients treated with regimens containing both E and V or high-dose P.
It has been postulated that male patients over 25 years of age treated with ctx may be more susceptible to persisting gonadal impairment than younger patients (Horwich et al., 1995; Leitner et al., 1986) . A toxicity-age correlation could be seen for FSH levels in our patients and statistically significant differences of LH and FSH elevations were found in patients <28 vs ) 28 years after treatment when lowtoxicity regimens were considered. As this result is not consistent for all patient groups and as the physiological increase of gonadotropins with age may represent a bias for interpretation (Blackman et al., 1988) , this issue will need further investigation.
As corticosteroids cause oligospermia and low sperm motility (Mancini et al., 1966) , we analysed gonadal toxicity with respect to the use of high-dose antiemetic steroids during therapy. No influence of steroids could be established. In a study by Hendry et al. in 1983 patients with severely depressed sperm counts before ctx had shown a greater potential for recovery after ctx than those with normal counts. However, pharmacological gonadal protection with LH-releasing hormone analogues applied during ctx has so far failed to achieve the protection promised by earlier experimental studies (Krause and Pflueger, 1989) . Accordingly, in our patients, suppressed FSH levels, as noted in 3 of 14 patients screened before ctx, did not protect against gonadal toxicity. 17a-OH-progesterone constitutes quantitatively the second steroid secreted from the testis (Horton, 1990) . Its function in man is not known -it does not seem to be a sex steroid or a regulator of gonadotropins. Therefore, our observation that 17a-OH-progesterone levels correlated with LH and testosterone, and increased significantly with the extent of tubular damage remains without clinical interpretation.
DHEAS, a 15-androgen, is the major secretory steroidal product of the adrenal gland. Together with its unconjungated form, DHEA, these adrenal androgens had traditionally been considered to be solely prohormones of stronger sex steroids. Recently, it has become clear that, by means of steroid sulphotransferase/sulphate interconvertable hormones, they themselves participate in a striking number of physiological and pathological processes (Parker, 1995) , although gross symptoms of clinical withdrawal following experimental adrenalectomy are not observed (Regelson et al., 1994) . The metabolism of DHEAS with its unique physiological age-dependent decline after a peak at the age of approx 24 years (Orentreich et al., 1984) has been considered as a marker for life expectancy and biological ageing (Barrett-Connor et al., 1986) . Despite a circadian rhythm, single-spot samples measured at a standardised time of day can give representative information on DHEAS levels (Bain et al., 1988) .
In our patients DHEAS levels were negatively correlated with age as expected, but DHEA levels failed to show this age-dependent fluctuation. However, DHEA levels correlated highly significantly to the cumulative P dose applied, as well as to LH and FSH levels. Furthermore, an influence of the cumulative doses of E and V was established, postulating an effect of combination ctx on DHEA metabolism, thus altering normal age ranges. Despite the high variability in DHEA level measurements (Zumoff et al., 1980) , correlation coefficients from 0.51 to 0.66 with levels of statistical significance from P<0.001 to <0.006 for DHEA levels and toxicity parameters in our patients indicate more than coincidental hormone distributions.
Since DHEA/DHEAS ratios are not constant interindividual variables, but rather dependent on numerous knowne.g. the extremely interindividual variable activity of the converting enzyme steroid sulphotransferase (Aksoy et al., 1993) -and unknown factors (Liu et al., 1990; Zumoff et al., 1980) , the influence and mechanisms of 'treatment toxicity' on DHEA/S levels are difficult to interpret. LeBlanc et al. (1992) and Maines et al. (1990) have shown that cisplatin has an impact on steroidogenic pathways by influencing the regulation of the cytochrome system as well as altering the testicular mitochondrial sidechain cleavage activity. Yet, the exact sites and definite mechanisms of metabolic dysregulation, especially in long-term toxicity, have not been determined and especially the clinical significance of possible interference with the physiological age-distribution of the adrenal androgens will remain to be investigated.
Oestrogens and androgens may play an important role in the development of risk factors for cardiovascular disease and the association of these steroid hormones with lipid profiles (Haffner et al., 1993) al., 1990; Schwabe et al., 1992) . The frequency of cholesterol elevations in 32% of our patients was accordingly higher than would normally be expected in a rather young population and age-stratified comparisons with reference groups (Assmann et al., 1986) showed significantly higher cholesterol levels especially in the 19-29 year-old patients. This finding is of concern as an increased incidence of arterial hypertension and of myocardial infarctions after ctx for testicular cancer has been postulated (Berger et al., 1995; Bissett et al., 1990; Gietema et al., 1992; Roth et al., 1988; Schwabe et al., 1992 
